TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7627386

Group type: EXPERIMENTAL
Intervention: Ranitidine, 100 mg IV twice a day for two days, followed by 150 mg orally twice a day for three days
Number of subjects: 23

Group type: COMPARATOR
Intervention: No ranitidine
Number of subjects: 23
Study: 1783090

Group type: EXPERIMENTAL
Intervention: Dry air during exercise followed by dry air after exercise (DD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dry air during exercise followed by humid air after exercise (DH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Humid air during exercise followed by dry air after exercise (HD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Humid air during exercise followed by humid air after exercise (HH)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recovery in dry air after exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Recovery in humid air after exercise
Number of subjects: 12
Study: 7240598

Group type: EXPERIMENTAL
Intervention: Unmodified ragweed extract (RW)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde polymer of ragweed extract (PRW)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 30980561

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Open Flap Debridement (OFD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups (OFD and GTR)
Number of subjects: 16
Study: 28536723

Group type: EXPERIMENTAL
Intervention: Two-way SMS medication reminders
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 47
Study: 26384233

Group type: EXPERIMENTAL
Intervention: Low dose of alcohol intake (0.4 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo intake
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Focus not on alcohol condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Explicit judgment on beverage-related cues
Number of subjects: 12
Study: 23690322

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: At-home exercise
Number of subjects: 90
Study: 21346338

Group type: EXPERIMENTAL
Intervention: Individualised body temperature dialysis (HD(ind))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Haemodialysis at 37°C (HD(37))
Number of subjects: 11
Study: 20137473

Group type: EXPERIMENTAL
Intervention: 10 microg recombination yeast hepatitis B vaccine (3 doses at 0 month, 1st month, 6th month)
Number of subjects: 568

Group type: COMPARATOR
Intervention: Control group (age > 18)
Number of subjects: 568
Study: 18297891

Group type: EXPERIMENTAL
Intervention: Iron supplementation (usually in combination with folic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Universal iron supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for anemia and targeted supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Withholding iron supplementation until treatment schedule is complete
Number of subjects: 0
Study: 14711565

Group type: EXPERIMENTAL
Intervention: Follicle aspiration set (FAS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard needle (Echotip)
Number of subjects: 300
Study: 11476462

Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg q.d.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Oxatomide 25 mg q.d.
Number of subjects: 62
Study: 9170765

Group type: EXPERIMENTAL
Intervention: TP (treatment-plan-related tasks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: UA (urine samples testing negative for illicit drugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: STD (standard treatment)
Number of subjects: 0
Study: 7711089

Group type: EXPERIMENTAL
Intervention: Brief intervention (BI), a one-session motivational interview
Number of subjects: 121

Group type: COMPARATOR
Intervention: Non-intervention control condition (NIC)
Number of subjects: 121
Study: 2906783

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 29648514

Group type: EXPERIMENTAL
Intervention: 3 × 50 min/wk of supervised center‐based walking (n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No-exercise (n = 13)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 27
Study: 25802346

Group type: EXPERIMENTAL
Intervention: Enhanced care management with motivational and parent management techniques
Number of subjects: 156

Group type: COMPARATOR
Intervention: Basic collaborative care management
Number of subjects: 156
Study: 23063633

Group type: EXPERIMENTAL
Intervention: 320 mg daily of saw palmetto extract
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: 640 mg daily of saw palmetto extract
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: 960 mg daily of saw palmetto extract
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 20650382

Group type: EXPERIMENTAL
Intervention: 90 degrees stylet
Number of subjects: 120

Group type: COMPARATOR
Intervention: 60 degrees stylet
Number of subjects: 120
Study: 18065796

Group type: EXPERIMENTAL
Intervention: Acetate-Free Biofiltration with constant potassium (2.5 mEq/l) (AFB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acetate-Free Biofiltration with decreasing intra-HD potassium (AFBK)
Number of subjects: 30
Study: 17239094

Group type: EXPERIMENTAL
Intervention: A‐CPVA (aggressive circumferential pulmonary vein ablation) group, n = 50
Number of subjects: 100

Group type: COMPARATOR
Intervention: M‐CPVA (modified circumferential pulmonary vein ablation) group, n = 50
Number of subjects: 100
Study: 12972523

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m2 IV on days 1 and 8, and cisplatin 100 mg/m2 IV on day 1 (GC arm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Irinotecan 150 mg/m2 IV on day 1 and cisplatin 80 mg/m2 IV on day 1 (IC arm)
Number of subjects: 80
Study: 10358993

Group type: EXPERIMENTAL
Intervention: Specific therapy and ultrasonic treatment (44 KHz, amplitude 2 microm to the paravertebral region and PT zones)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Specific therapy only
Number of subjects: 50
Study: 8665055

Group type: EXPERIMENTAL
Intervention: rhDNase 2.5 mg in 2.5 ml excipient twice a day (n = 43)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 2.5 ml excipient alone twice daily (n = 37)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both treatment groups (rhDNase and control)
Number of subjects: 80
Study: 1874198

Group type: EXPERIMENTAL
Intervention: Frusemide 0.5 mg kg‐1 at the onset of hypotension (Group F)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Labetalol induced hypotension in Groups E and I
Number of subjects: 25

Group type: COMPARATOR
Intervention: Labetalol induced hypotension in Group F
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Frusemide (Group F)
Number of subjects: 25
Study: 6352599

Group type: EXPERIMENTAL
Intervention: Azlocillin (18 g/day, intravenously)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Gentamicin (3 to 5 mg/kg/day, intramuscularly)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Azlocillin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 49
Study: 3894470

Group type: EXPERIMENTAL
Intervention: Reduced cost sharing (coinsurance rate falls from 95% to 0%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More generous coverage in the first year
Number of subjects: 0
Study: 29713850

Group type: EXPERIMENTAL
Intervention: Experience Focussed Counselling (EFC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treatment As Usual
Number of subjects: 25
Study: 27402237

Group type: EXPERIMENTAL
Intervention: Best Endovascular Therapy
Number of subjects: 2100

Group type: COMPARATOR
Intervention: Best Surgical Therapy
Number of subjects: 2100
Study: 24097439

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (dual therapy)
Number of subjects: 5045

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 5045
Study: 22803968

Group type: EXPERIMENTAL
Intervention: Terumo Capiox FX25 (Group-T)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sorin Synthesis (Group-S)
Number of subjects: 80
Study: 20160062

Group type: EXPERIMENTAL
Intervention: IDH1 mutations
Number of subjects: 159

Group type: COMPARATOR
Intervention: PCV chemotherapy
Number of subjects: 159
Study: 18657891

Group type: EXPERIMENTAL
Intervention: Serum phosphorus level greater than 6 mg/dL
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Serum calcium level greater than 11 mg/dL
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Ca x P product greater than 50 mg(2)/dL(2)
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Phosphorus, calcium, and Ca x P product values
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: Intact parathyroid hormone levels
Number of subjects: 1846
Study: 15820416

Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12593498

Group type: COMPARATOR
Intervention: Acute myocardial infarction (AMI)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Unstable angina pectoris (UAP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Stable angina pectoris (SAP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Healthy controls
Number of subjects: 59
Study: 10510219

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (221 +/- 18 mg; range 60-360 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral alendronate 40 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous pamidronate 60 mg every 3 months
Number of subjects: 60
Study: 8725987

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.2 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tropisetron (5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 60
Study: 1763596

Group type: EXPERIMENTAL
Intervention: Ketamine 0.7 mg/kg BW i.v. before anaesthesia, and 0.35 mg/kg BW 15 and 30 min after the first dose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl 1.5 mg/kg BW i.v. before anaesthesia
Number of subjects: 30
Study: 7157926

Group type: EXPERIMENTAL
Intervention: Streptokinase 500,000 IU within 30 min
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Streptokinase 1,500,000 IU within 60 min
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no streptokinase treatment)
Number of subjects: 93
Study: 31796519

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg IV every 21 days and Vorinostat 400 mg orally 5 days on and 2 days off during each 21-day cycle
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) in all patients
Number of subjects: 50
Study: 30936281

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28983665

Group type: EXPERIMENTAL
Intervention: Prebiotic vaginal gel (5 mg) plus three 250 mg metronidazole tablets per day for 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole tablet alone (three 250 mg tablets per day for 7 days)
Number of subjects: 100
Study: 27029815

Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 106
Study: 24475766

Group type: EXPERIMENTAL
Intervention: Self Determination Theory-based exercise referral intervention
Number of subjects: 347

Group type: COMPARATOR
Intervention: Standard provision exercise referral
Number of subjects: 347

Group type: EXPERIMENTAL
Intervention: Both interventions (SDT and standard provision)
Number of subjects: 347
Study: 22748465

Group type: EXPERIMENTAL
Intervention: Plasma IL-21 concentration at baseline (mean 46 h)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasma IL-21 concentration at 24 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline IL-21 correlation with ΔLVESVI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline IL-21 correlation with change in LV end-diastolic volume index
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Plasma IL-21 as an independent predictor of remodelling
Number of subjects: 100
Study: 20495510

Group type: EXPERIMENTAL
Intervention: Delayed Tac with daclizumab induction
Number of subjects: 199

Group type: COMPARATOR
Intervention: Standard Tac
Number of subjects: 199
Study: 18041436

Group type: COMPARATOR
Intervention: Glucomannan (1 g) before 75-g glucose load
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucomannan (3 g/day for 4 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16118723

Group type: EXPERIMENTAL
Intervention: Glycerin suppository
Number of subjects: 0
Study: 11509289

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted system (Group V)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Siphon-dependent system (Group S)
Number of subjects: 60
Study: 9755295

Group type: EXPERIMENTAL
Intervention: Fleroxacin (200 mg IV)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg IV)
Number of subjects: 24
Study: 7823260

Group type: EXPERIMENTAL
Intervention: 75 mg aspirin (ASA) administered daily for two weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (non-pregnant subjects)
Number of subjects: 21
Study: 3392236

Group type: EXPERIMENTAL
Intervention: 0.5 mg of loprazolam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 mg of loprazolam
Number of subjects: 16
Study: 30298608

Group type: EXPERIMENTAL
Intervention: Immediate treatment (ART at study enrollment)
Number of subjects: 4580

Group type: COMPARATOR
Intervention: Deferred treatment (ART when CD4 count fell below 350 cells/µL)
Number of subjects: 4580
Study: 27838831

Group type: EXPERIMENTAL
Intervention: Endoscopic total extraperitoneal repair (TEP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open Lichtenstein repair
Number of subjects: 60
Study: 25760804

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg once daily)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Naltrexone and Placebo (combined)
Number of subjects: 221
Study: 25045726

Group type: EXPERIMENTAL
Intervention: Single intramuscular injection of vitamin E + selenium 3 weeks prepartum
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daily supplementation of oral vitamin E from 3 weeks prepartum to parturition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Injective vitamin E + selenium with daily supplementation of oral vitamin E
Number of subjects: 60
Study: 21849399

Group type: EXPERIMENTAL
Intervention: Patients with metabolic syndrome
Number of subjects: 462

Group type: COMPARATOR
Intervention: Patients without metabolic syndrome
Number of subjects: 462
Study: 19318111

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet (30/40/30% of energy of protein/carbohydrate/fat)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Adequate Protein (AP) diet (10/60/30% of energy of protein/carbohydrate/fat)
Number of subjects: 10
Study: 17653531

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise for 10 minutes
Number of subjects: 45

Group type: COMPARATOR
Intervention: Positive expectation manipulation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Negative expectation manipulation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Neutral expectation manipulation
Number of subjects: 45
Study: 15310772

Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention (SDMI)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 11522161

Group type: EXPERIMENTAL
Intervention: Brief proactive educational intervention over the telephone with two follow-up mailouts
Number of subjects: 1717
Study: 9131946

Group type: EXPERIMENTAL
Intervention: S-flurbiprofen (75 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: R-flurbiprofen (75 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 11
Study: 8395177

Group type: EXPERIMENTAL
Intervention: Parodontax dentifrice
Number of subjects: 128

Group type: COMPARATOR
Intervention: Calcium carbonate placebo dentifrice
Number of subjects: 128
Study: 3526824

Group type: EXPERIMENTAL
Intervention: Exercise (running)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Meditation
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 60
Study: 28993177

Group type: EXPERIMENTAL
Intervention: DKK1 at T1 (CR)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: DKK1 at T2 (4 months before relapse)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: DKK1 at T3 (relapse)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sclerostin at T1 (CR)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sclerostin at T2 (4 months before relapse)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Sclerostin at T3 (relapse)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: P1NP at T1 (CR)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: P1NP at T2 (4 months before relapse)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: P1NP at T3 (relapse)
Number of subjects: 69
Study: 27077337

Group type: EXPERIMENTAL
Intervention: Intervention group with CHW-led sessions
Number of subjects: 203

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 203
Study: 25547003

Group type: EXPERIMENTAL
Intervention: Intraperitoneal raltitrexed in normal saline (500 ml)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Normal saline (500 ml)
Number of subjects: 91
Study: 22925840

Group type: EXPERIMENTAL
Intervention: Manual Aspiration (MA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional Chest Tube Drainage (TT)
Number of subjects: 56
Study: 20818903

Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel (600 mg loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter)
Number of subjects: 25086

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel (300 mg loading dose and 75 mg daily thereafter)
Number of subjects: 25086

Group type: EXPERIMENTAL
Intervention: Double-dose clopidogrel
Number of subjects: 25086

Group type: COMPARATOR
Intervention: Standard-dose clopidogrel
Number of subjects: 25086

Group type: EXPERIMENTAL
Intervention: Higher-dose aspirin (300 to 325 mg daily)
Number of subjects: 25086

Group type: COMPARATOR
Intervention: Lower-dose aspirin (75 to 100 mg daily)
Number of subjects: 25086

Group type: EXPERIMENTAL
Intervention: Higher-dose aspirin
Number of subjects: 25086

Group type: COMPARATOR
Intervention: Lower-dose aspirin
Number of subjects: 25086
Study: 18268067

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 15
Study: 15778953

Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadodiamide
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadodiamide
Number of subjects: 30
Study: 12663712

Group type: COMPARATOR
Intervention: Conventional chemotherapy (MACOP-B regimen)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Abbreviated chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (HDT-ASCT)
Number of subjects: 150
Study: 10362762

Group type: EXPERIMENTAL
Intervention: Men (M) and Women (W) matched by VO2 max (46.1 +/- 2.0 and 43.6 +/- 2.9 ml. kg‐1. min‐1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Men (MF) with higher fitness level (VO2 max of 59.1 +/- 1.8 ml. kg‐1. min‐1)
Number of subjects: 25
Study: 8895239

Group type: EXPERIMENTAL
Intervention: Active PSW
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo PSW
Number of subjects: 92

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 92
Study: 8315433

Group type: EXPERIMENTAL
Intervention: Busulfan (BU) and cyclophosphamide (CY) with total-body irradiation (TBI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Busulfan (BU) and cyclophosphamide (CY) without TBI
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Marrow treated with 4-hydroperoxycyclophosphamide (4-HC)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 47
Study: 2423798

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study: 29277134

Group type: EXPERIMENTAL
Intervention: Customized bandages
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unmarked bandages
Number of subjects: 90
Study: 27392262

Group type: EXPERIMENTAL
Intervention: Erector Spinae Taping
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo Taping
Number of subjects: 44
Study: 23560476

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel
Number of subjects: 52

Group type: COMPARATOR
Intervention: aqueous gel
Number of subjects: 52
Study: 22676644

Group type: EXPERIMENTAL
Intervention: Mental Imagery (MI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Textbook reading (No MI)
Number of subjects: 50
Study: 19955879

Group type: EXPERIMENTAL
Intervention: Self-esteem program incorporated into health and physical education curriculum (32 weeks, 3 sessions of 45 minutes each week)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Self-esteem program for girls
Number of subjects: 184

Group type: COMPARATOR
Intervention: Regular health and physical education curriculum (no self-esteem program)
Number of subjects: 184
Study: 17400686

Group type: EXPERIMENTAL
Intervention: Collins CPL (Ferraris Respiratory; Louisville, CO)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Morgan Transflow Test PFT System (Morgan Scientific; Haverhill, MA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: SensorMedics Vmax 22D (VIASYS Healthcare; Yorba Linda, CA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Jaeger USA Masterscreen Diffusion TP (VIASYS Healthcare; Yorba Linda, CA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Medical Graphics Profiler DX System (Medical Graphics Corporation; St. Paul, MN)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All instruments
Number of subjects: 11
Study: 15351856

Group type: EXPERIMENTAL
Intervention: CYP2C9 genotyping prior to initiation of warfarin therapy (genotyped group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care of an anticoagulation clinic (non-genotyped group)
Number of subjects: 0